Hauptinhalt
Liste der Publikationen des Instituts aus dem Jahre 2016
Berns K & A Sonnenblick & A Gennissen & S Brohée & E M Hijmans & B Evers & D Fumagalli & C Desmedt & S Loibl & C Denkert & P Neven & W Guo & F Zhang & T A Knijnenburg & T Bosse & M S van der Heijden & S Hindriksen & W Nijkamp & L F A Wessels & H Joensuu & G B Mills & R L Beijersbergen & C Sotiriou & R Bernards (2016)
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
in: Clinical Cancer Research (22)
10.1158/1078-0432.CCR-15-2996
Budczies J & N Pfarr & A Stenzinger & D Treue & V Endris & F Ismaeel & N Bangemann & J-U Blohmer & M Dietel & S Loibl & F Klauschen & W Weichert & C Denkert (2016)
Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment
in: Oncotarget (7)
10.18632/oncotarget.7451
Budczies J & M Bockmayr & C Denkert & F Klauschen & S Gröschel & S Darb-Esfahani & N Pfarr & J Leichsenring & M L Onozato & J K Lennerz & M Dietel & S Fröhling & P Schirmacher & A J Iafrate & W Weichert & A Stenzinger (2016)
Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival
in: Genes, Chromosomes & Cancer (55)
10.1002/gcc.22365
Budczies J & C Denkert (2016)
Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome
in: Recent Results in Cancer Research (207)
10.1007/978-3-319-42118-6_7
Buus R & I Sestak & R Kronenwett & C Denkert & P Dubsky & K Krappmann & M Scheer & C Petry & J Cuzick & M Dowsett (2016)
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
in: Journal of the National Cancer Institute (108)
10.1093/jnci/djw149
Darb-Esfahani S & C A Kunze & H Kulbe & J Sehouli & S Wienert & J Lindner & J Budczies & M Bockmayr & M Dietel & C Denkert & I Braicu & K Jöhrens (2016)
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
in: Oncotarget (7)
10.18632/oncotarget.6429
Darb-Esfahani S & C Denkert & A Stenzinger & C Salat & B Sinn & C Schem & V Endris & P Klare & W Schmitt & J-U Blohmer & W Weichert & M Möbs & H Tesch & S Kümmel & P Sinn & C Jackisch & M Dietel & T Reimer & S Loi & M Untch & G von Minckwitz & V Nekljudova & S Loibl (2016)
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
in: Oncotarget (7)
10.18632/oncotarget.11891
Denkert C & F Schütz (2016)
Immunological Mechanisms in Breast Cancer - from Bench to Bedside
in: Breast Care (11)
10.1159/000446266
Denkert C & S Wienert & A Poterie & S Loibl & J Budczies & S Badve & Z Bago-Horvath & A Bane & S Bedri & J Brock & E Chmielik & M Christgen & C Colpaert & S Demaria & G Van den Eynden & G Floris & S B Fox & D Gao & B Ingold Heppner & S R Kim & Z Kos & H H Kreipe & S R Lakhani & F Penault-Llorca & G Pruneri & N Radosevic-Robin & D L Rimm & S J Schnitt & B V Sinn & P Sinn & N Sirtaine & S A O'Toole & G Viale & K Van de Vijver & R de Wind & G von Minckwitz & F Klauschen & M Untch & P A Fasching & T Reimer & K Willard-Gallo & S Michiels & S Loi & R Salgado (2016)
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
in: Modern Pathology (29)
10.1038/modpathol.2016.109
Gossmann J & M Stolte & M Lohoff & P Yu & R Moll & F Finkernagel & H Garn & C Brendel & A Bittner & A Neubauer & M Q Huynh (2016)
A Gain-Of-Function Mutation in the Plcg2 Gene Protects Mice from Helicobacter felis-Induced Gastric MALT Lymphoma
in: PloS One (11)
10.1371/journal.pone.0150411
Hilvo M & I de Santiago & P Gopalacharyulu & W D Schmitt & J Budczies & M Kuhberg & M Dietel & T Aittokallio & F Markowetz & C Denkert & J Sehouli & C Frezza & S Darb-Esfahani & E I Braicu (2016)
Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas
in: Cancer Research (76)
10.1158/0008-5472.CAN-15-2298
Ingold Heppner B & S Loibl & C Denkert (2016)
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer
in: Breast Care (11)
10.1159/000444357
Ingold Heppner B & M Untch & C Denkert & B M Pfitzner & B Lederer & W Schmitt & H Eidtmann & P A Fasching & H Tesch & C Solbach & M Rezai & D M Zahm & F Holms & M Glados & P Krabisch & E Heck & A Ober & P Lorenz & K Diebold & J-O Habeck & S Loibl (2016)
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
in: Clinical Cancer Research (22)
10.1158/1078-0432.CCR-15-2338
Kirschbaum A & F Rüdell & A Pehl & D K Bartsch (2016)
More compression improves sealing effect on larger pulmonary arteries
in: The Journal of Surgical Research (201)
10.1016/j.jss.2015.09.031
Krug S & M Boch & P Rexin & A Pfestroff & T Gress & P Michl & A Rinke (2016)
Acromegaly in a patient with a pulmonary neuroendocrine tumor: case report and review of current literature
in: BMC research notes (9)
10.1186/s13104-016-2132-1
Loi S & S Dushyanthen & P A Beavis & R Salgado & C Denkert & P Savas & S Combs & D L Rimm & J M Giltnane & M V Estrada & V Sánchez & M E Sanders & R S Cook & M A Pilkinton & S A Mallal & K Wang & V A Miller & P J Stephens & R Yelensky & F D Doimi & H Gómez & S V Ryzhov & P K Darcy & C L Arteaga & J M Balko (2016)
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
in: Clinical Cancer Research (22)
10.1158/1078-0432.CCR-15-1125
Loibl S & S Darb-Esfahani & J Huober & A Klimowicz & J Furlanetto & B Lederer & A Hartmann & H Eidtmann & B Pfitzner & P A Fasching & K Tiemann & C Jackisch & K Mehta & G von Minckwitz & M Untch & C Denkert (2016)
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
in: Clinical Cancer Research (22)
10.1158/1078-0432.CCR-15-0965
Mack E & K Stabla & J Riera-Knorrenschild & R Moll & A Neubauer & C Brendel (2016)
A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing
in: BMC cancer (16)
10.1186/s12885-016-2589-2
Manoharan J & C L Lopez & K Hackmann & M B Albers & A Pehl & P H Kann & E P Slater & E Schröck & D K Bartsch (2016)
An unusual phenotype of MEN1 syndrome with a SI-NEN associated with a deletion of the MEN1 gene
in: Endocrinology, Diabetes & Metabolism Case Reports (2016)
10.1530/EDM-16-0011
Marmé F & B Lederer & J-U Blohmer & S D Costa & C Denkert & H Eidtmann & B Gerber & C Hanusch & J Hilfrich & J Huober & C Jackisch & S Kümmel & S Loibl & S Paepke & M Untch & G von Minckwitz & A Schneeweiss (2016)
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy
in: European Journal of Cancer (53)
10.1016/j.ejca.2015.09.022
Savas P & R Salgado & C Denkert & C Sotiriou & P K Darcy & M J Smyth & S Loi (2016)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
in: Nature Reviews. Clinical Oncology (13)
10.1038/nrclinonc.2015.215
Steven A & S Leisz & K Sychra & B Hiebl & C Wickenhauser & D Mougiakakos & R Kiessling & C Denkert & B Seliger (2016)
Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization
in: Oncotarget (7)
10.18632/oncotarget.10474
Striefler J K & M Sinn & U Pelzer & A Jühling & L Wislocka & M Bahra & B V Sinn & C Denkert & B Dörken & H Oettle & H Riess & H Bläker & P Lohneis (2016)
P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment
in: Pathology, Research and Practice (212)
10.1016/j.prp.2016.06.001
Taube E T & C Denkert & J Sehouli & C A Kunze & M Dietel & I Braicu & A Letsch & S Darb-Esfahani (2016)
Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma
in: Gynecologic Oncology (140)
10.1016/j.ygyno.2015.12.018
Untch M & C Jackisch & A Schneeweiss & B Conrad & B Aktas & C Denkert & H Eidtmann & H Wiebringhaus & S Kümmel & J Hilfrich & M Warm & S Paepke & M Just & C Hanusch & J Hackmann & J-U Blohmer & M Clemens & S Darb-Esfahani & W D Schmitt & S Dan Costa & B Gerber & K Engels & V Nekljudova & S Loibl & G von Minckwitz & German Breast Group (GBG) & Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators (2016)
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial
in: The Lancet. Oncology (17)
10.1016/S1470-2045(15)00542-2
Vogiatzi F & D T Brandt & J Schneikert & J Fuchs & K Grikscheit & M Wanzel & E Pavlakis & J P Charles & O Timofeev & A Nist & M Mernberger & E J Kantelhardt & U Siebolts & F Bartel & R Jacob & A Rath & R Moll & R Grosse & T Stiewe (2016)
Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5
in: Proceedings of the National Academy of Sciences of the United States of America (113)
10.1073/pnas.1612711114